Skip to main content

Spectrum: Autism Research News

Tag: null and noteworthy

September 2022
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Brain aging, oxytocin pathways, biomarker back-up

by  /  15 September 2022

Null and replicated results in this month’s newsletter tackle aging, a purported pathway for oxytocin’s effects on autistic people, and a possible autism biomarker.

Comments
August 2022
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Mind reading, specialist shortage, sleep problems source

by  /  23 August 2022

This month, a commonly used emotion-recognition test doesn’t perform as expected — nor does a survey of past efforts to train autism specialists or a hunt for the sources of the sleep problems that often accompany the condition.

Comments
July 2022
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Metacognition, balovaptan bust, pattern recognition

by  /  21 July 2022

This month, we pore over null results from a study of the accuracy of emotion recognition skills in autistic people, clinical trials of a vasopressin drug called balovaptan, and an analysis of ‘systemizing’ abilities in autistic children.

Comments
June 2022
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: INSAR keynote, typical cerebellums, social subdomains

by  /  9 June 2022

In this edition, researchers sink a purported link between cerebellar volume and autism and buoy a theory about measuring social behaviors.

Comments
May 2022
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Sex bias and gender blend

by  /  9 May 2022

In this edition, a diagnostic measure shows no significant differences between sexes, and a survey confirms increased gender diversity among children with autism.

Comments
April 2022
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: An ineffective therapy and an effective biomarker

by  /  6 April 2022

In this edition, a strategy to help autistic children adapt their skills to new situations shows no benefit, but an early-life autism biomarker does.

Comments
March 2022
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results

Null and Noteworthy: Halted vasopressin trial, intact visual memory, a new way to study emotions

by  /  10 March 2022

In this edition of Null and Noteworthy, a large clinical trial goes sideways, while memory and emotions hold up.

Comments
February 2022
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results

Null and Noteworthy: Autism and aging, anorexia overlaps, pregnancy effects

by  /  10 February 2022

In this edition of Null and Noteworthy, researchers replicate encouraging findings on autism and aging and shoot down a host of potential links between pregnancy complications and having a child with autism.

Comments
December 2021
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results

Null and Noteworthy: Quality of life, IACC discussion, mixed results on interventions

by  /  2 December 2021

In this edition of Null and Noteworthy, the Interagency Autism Coordinating Committee grapples with “groundbreaking” research and two reviews of interventions come to conflicting conclusions.

Comments
September 2021
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results

Null and Noteworthy: Null rejection, repetitive behaviors, unsuccessful treatments

by  /  23 September 2021

In this edition of Null and Noteworthy, tests of intranasal oxytocin and an Angelman syndrome treatment fail to see results.

Comments